1,2,3,4-Tetrahydroisoquinoline (THIQ) as privileged scaffold for anticancer de novo drug design

Please use this identifier to cite or link to this item: http://dspace.bits-pilani.ac.in:8080/jspui/handle/123456789/13344

Full metadata record

DC Field	Value	Language
dc.contributor.author	Murugesan, Sankaranarayanan	-
dc.date.accessioned	2023-12-11T10:42:20Z	-
dc.date.available	2023-12-11T10:42:20Z	-
dc.date.issued	2021-04	-
dc.identifier.uri	https://www.tandfonline.com/doi/full/10.1080/17460441.2021.1916464	-
dc.identifier.uri	http://dspace.bits-pilani.ac.in:8080/xmlui/handle/123456789/13344	-
dc.description.abstract	Cancer is a dreadful disorder that is emerging as one of the leading causes of mortality across the globe. The complex tumor environment, supplemented with drawbacks of the existing drugs, has made it a global health concern. The Tetrahydroisoquinoline (THIQ) ring holds an important position in medicinal chemistry due to its wide range of pharmacological properties. Several THIQ based natural products have been previously explored for their antitumor properties, making it a vital scaffold for anticancer drug design.	en_US
dc.language.iso	en	en_US
dc.publisher	Taylor & Francis	en_US
dc.subject	Pharmacy	en_US
dc.subject	Tumor	en_US
dc.subject	Benzo piperidine	en_US
dc.subject	3, 4-dihydro-1H-isoquinoline	en_US
dc.subject	1, 2, 3, 4-tetrahydro-2-azanaphthalene	en_US
dc.subject	Synthesis	en_US
dc.subject	Epigenetics	en_US
dc.title	1,2,3,4-Tetrahydroisoquinoline (THIQ) as privileged scaffold for anticancer de novo drug design	en_US
dc.type	Article	en_US
Appears in Collections:	Department of Pharmacy

Files in This Item:

There are no files associated with this item.